Impact of rotavirus vaccination on laboratory confirmed cases in Belgium

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4698-4703

  Hanquet, Germaine ^a,b   Ducoffre, Geneviève ^a   Vergison, Anne ^c,d   Neels, Pieter ^e   Sabbe, Martine ^a   Van Damme, Pierre ^e   Van Herck, Koen ^f,g  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b independent environmental consultant at Easton Consult SPRL   (Belgium)

^c HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^d Federal Agency for Medicines and Health Products Belgium   (Belgium)

^e EUROPEAN MEDICINES AGENCY   (United Kingdom)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g GHENT UNIVERSITY   (Belgium)

Author keywords

Epidemiology; Rotavirus vaccine; Surveillance and monitoring

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; BELGIUM; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SURVEILLANCE; HEALTH SURVEY; HUMAN; INCIDENCE; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS; ROTAVIRUS INFECTION; SEASONAL VARIATION; VACCINATION;

EID: 79960645081     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.098     Document Type: Article

References (25)

1. Centers for Disease C, Prevention. Rotavirus surveillance-worldwide, 2001-2008. MMWR Morb Mortal Weekly Rep 2008;57(46):1255-7.
2. Bilcke J, Van Damme P, De Smet F, Hanquet G, Van Ranst M, Beutels P. The health and economic burden of rotavirus disease in Belgium. Eur J Pediatr 2008;167(12 (December)):1409-19.
3. The Pediatric Rotavirus European Committee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006;134(5 (October)):908-16.
4. Forster J, Guarino A, Parez N, Moraga F, Roman E, Mory O, et al. Hospitalbased surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009;123(3 (March)):393-400.
5. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11-22.
6. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33.
7. Anonymous. Deuxième vaccin contre le rotavirus: Rotateq ®. Attention: différences avec le Rotarix® concernant la posologie et le coût. Folia Pharmacotherap 2007;34:61.
8. World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. Geneva; 2008.
9. Hoppenbrouwers K, Van Damme P, Vandermeulen C, Theeten H, Boonen M, Roelants M. Studie van de vaccinatiegraad bij jonge kinderen en adolescenten in Vlaanderen in 2008. Brussels; 2009.
10. Robert E, Swennen B. Enquête de couverture vaccinale des enfants de 18 à 24 mois en communauté franç aise (Bruxelles excepté). Brussels: ULB; November 2009.
11. Vandenberghe H. Estimation of the national representativeness of the SLN. In: ISP/WIV, editor. Diagnostic and surveillance of infectious diseases, 26 November 2004. Brussels. 2004. p. 19-27.
12. CDC. Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMWR Morb Mortal Weekly Rep 2008;57(25):697-700.
13. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009;124(2): 465-71.
14. Halloran ME, Struchiner CJ, Longini Jr IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997;146(10):789-803.
15. Raes M, Strens D, Vergison A, Verghote M, Standaert B. Second year postrotavirus vaccination in Belgium: impact on rotavirus positive stool samples in hospitalized children. In: 28th meeting of the European Society for Paediatric Infectious Diseases. 2010.
16. Atchison C, Lopman B, Edmunds WJ. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010;28(18):3118-26.
17. Parashar UD, Glass RI. Rotavirus vaccines-early success, remaining questions. N Engl J Med 2009;360(11):1063-5.
18. Koch J, Wiese-Posselt M. Epidemiology of rotavirus infections in children <5 years of age: Germany, 2001-2008. Pediatr Infect Dis J 2010 [Publish Ahead of Print].
19. Strens DVSJ, Standaert B. To investigate the effect of paediatric vaccination on rotavirus disease burden in Belgium. Pediatr Infect Dis J 2009;28(6 (June)):200-1.
20. Raes MVM, Mewis A. Rotavirus gastroenteritis after launching rotavirus vaccines: epidemiological data from a regional hospital in Belgium. In: 28th meeting of the European Society for Paediatric Infectious Diseases. 2010.
21. Raes MSD, Vergison A, Verghote M, Standaert B. Second year post-rotavirus vaccination in Belgium: impact on rotavirus positive stool samples in hospitalized children. In: 28th meeting of the European Society for Paediatric Infectious Diseases. 2010.
22. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011;30(1 Suppl):S21-4.
23. Raes M, Strens D, Vergison A, Verghote M, Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 2011, doi:10.1097/INF.0b013e318214b811 [Publish Ahead of Print].
24. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J 2009;29(4 (April)):319-23.
25. Ducoffre G. Surveillance des Maladies Infectieuses par un Réseau de Laboratoires de Microbiologie 2009. Brussels: Scientific Institute of Public Health; 2010.